期刊
MULTIPLE SCLEROSIS JOURNAL
卷 27, 期 14, 页码 2280-2283出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/13524585211006372
关键词
Vaccination; yellow fever; travel; multiple sclerosis; yellow fever vaccination
资金
- French State [ANR-10-COHO-002]
- Eugene Devic EDMUS Foundation against multiple sclerosis
- ARSEP Foundation
The study conducted on the French national cohort found that the yellow fever vaccine (YFV) does not worsen the course of relapsing-remitting multiple sclerosis (RR-MS).
Background: Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses. Objective: To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV. Methods: Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS. Results: 128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) (p = 0.92). Time to first relapse was not different between groups (adjusted hazard ratio (HR) = 1.33; 95% confidence interval (CI) = 0.53-3.30, p = 0.54). Conclusion: These results suggest that YFV does not worsen the course of RR-MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据